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Condorelli et al. (1) reported the results of a randomized, multicenter 
clinical trial that compared sulodexide with standard therapy in 3,9% 
survivors of acute my~ard%l infarction. First. we were very surprised 
that the control patie& did not receive aspirin, which is obviously vcv 
e&&e in this etting.! Moreover, aspirin treatment was an exclusion 
criteria. In the Discussion section of their report, the authors justify the 
absence of an aspirin-treated arm by the fact that when the trial was 
&ripcJ (in B&l), published reports had not yet shown a “clear 
bcncht from anlithrombtic therapy in terms of survival” (I). There is 
no iqdicatior of the actual trial duration, but WC can infer from the text 
that the trial was not stopped premi~t~r~l~ bccau,X of increasing 
evidence of the beneficial effect of aspirin in post-myocardial infarc- 
lion patientu. Hence, because of the large number of patients random- 
Bed and the relatively few ccntcrs involved, the reader can infer that 
the randomization process was continued even after the results of the 
ISI!% trial (2) were published. If this is true, thun several “control” 
patients did not receive effcctivr treatment because they were used as 
cr,ntrol subjects for a potentially beneficial one. We wonder why the 
Ethktl Committee or the Safety Monitoring Board did not stop the 
trial in view of the important new disclosures of the ISIS-2 invcstiga- 
tars. Second. with regard to the “written informed consent” that the 
patients gave before randomization, we suspect hat the consent form 
was not updated after the disclosure of the ISIS-2 results; otherwise. 
WC do rrclt understand why a patient would choose to enter a trial that 
deliberately denied (to half of the patients) a life-saving treatment. 
In reply to Fresco et al., wc would like to point out the following 
consideratinns. The IPO-V2 trial (I) begin on Mrrch 8, 198s and 
cnde4 on De&umber .3t_l, 1989. The recruitment period Wi\s concluded. 
therefore. on January I, 1989. The results of the ISIS-2 trial were 
published in August I988 (2). Thus, the vast majority of patients in the 
PO-V2 trial had already been enrolled by that time. 
With regard to the remaining patients who entered our study after 
the results of the ISIS-2 trial were made public, the Ethical Committee 
decided that even though the ISIS-2 was an important and well- 
conducted study, pending further confirmation of it< results hy other 
investigators the decision to stop the trial or to add aspirin to both 
arms of the study was not warranted. la retrospect, and in view of tbr 
debate concerning the use of aspirin in the management of post- 
myocardial infarction patients, we consider the decision of the Ethical 
Committee quite appropriate. We hope that these considerations will 
be shared by the readers of the Journal. 
Bancrjcc et al. (1) assert that the relation bctwcen end-systolic stress 
(ESS) and the mcun rate-corrcctrd velocity of shortening (VCF,) is 
nonlincur for any constant contractile state and should not bc used a~ 
an index of contractility. I do not believe that the data reported by 
Banerjcc et al. support this linding. There are also other problems with 
this study. 
Nonlinearity of the ESVCF, relation. WC investigated (2) this 
relation over a wide range of afterload. sampling 6 to IO different levels 
of afterload at a constant contraclilc state in each subject. The 
regression was linear and the slope was similar in dilfcrent subjects by 
linear and nonlinear regression analysis. Banerjcc et al. cite only our 
original investigation (2)” but these tindings have been substantiated in 
numerous subsequent investigations (3-10) in humans and in animals. 
Banerjee et al. propose that this large body of accumulated ata are 
incorrect on the basis of theoretic derivation of the ESS-VCF, relation 
from the V,,;,, index dcscrihcd by Sonnenblick and a flawed analysis of 
their own data. 
Although Banerjee ct al. state that the ESS-VCF, relation is 
derived from V,,,:,,, this is incorrect. The ESS-VCF, relation uses a 
mean normalized velocity. not a Tbak absolute velocity, and assesses 
afterload as end-systolic stress instead of the instantaneous tress at 
the instant of peak velocity. In an elegant series of experiments by Suga 
et al. (3) end-systolic stress has been shown to be the force limiting 
shortening and to hold no constant relation to stress at any point 
earlier in the cardiac cycle. The V,, is an isovolumic phase index, 
whereas ESS VCF, is an ejection phase index. Much 01’ the V,,, curve 
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